Sotio Starts Phase 1/2 Trial of DCVAC/PCa plus ONCOS-102 in Advanced Prostate Cancer

Sotio Starts Phase 1/2 Trial of DCVAC/PCa plus ONCOS-102 in Advanced Prostate Cancer
The first patient has enrolled in Sotio's Phase 1/2 clinical trial testing the immunotherapy DCVAC/PCa in combination with ONCOS-102 in men with advanced prostate cancer. The patient was enrolled in Prague, Czech Republic. According to Sotio, this is the first trial of a combination of cellular immunotherapy and viral therapy conducted by a company from Central and Eastern Europe (called the CEE). Patient recruitment in the SP015 study (2015-004314-15) is also expected in the U.K. Specifically, the SP015 trial (NCT03514836) is testing the safety and immune activation of DCVAC/PCa plus ONCOS-102 in men with metastatic castration-resistant prostate cancer. Sotio plans to enroll up to 15 patients whose disease worsened after initial treatment with either hormone therapy or chemotherapy. Targovax, the developer of ONCOS-102, is collaborating in the study. The trial's primary goal is to determine the length of time before a patient's prostate cancer worsens. Secondary objectives include overall survival, safety, time until PSA levels rise, and time without disease worsening on imaging scans. “We are very happy to have succeeded in initiating such a complex trial, the first of its kind ever conducted in the Czech Republic and the CEE region,” Radek Spisek, CEO of Sotio, said in a press release. "The SP015 clinical trial will help us to gather critical evidence necessary to develop innovative immunotherapies for the treatment of a cancer that threatens 1 in 5 men globally," he added. DCVAC/PCa is an immunotherapy based on the activation of a type of immune cell called dendritic cells, which are responsible for bringing harmful elements to cancer-fighting T-cells. The treatment uses the patient’s own cells and aims to produce an immune reaction again
Subscribe or to access all post and page content.